Fab is an antibody fragment that blocks the platelet glycoprotein (GP) Ib/IIIa receptor and potently inhibits platelet aggregation.
Background Patients with unstable angina despite intensive medical therapy, ie, refractory angina, are at high risk for developing thrombotic complications: myocardial infarction or coronary occlusion during percutaneous transluminal coronary angioplasty (PTCA). Chimeric 7E3 (c7E3) Fab is an antibody fragment that blocks the platelet glycoprotein (GP) Ib/IIIa receptor and potently inhibits platelet aggregation.
Methods and Results To evaluate whether potent platelet inhibition could reduce these complications, 60 patients with dynamic ST-T changes and recurrent pain despite intensive medical therapy were randomized to c7E3 Fab or placebo. After initial angiography had demonstrated a culprit lesion suitable for PTCA, placebo or c7E3 Fab was administered as 0.25 mg/kg bolus injection followed by 10 ,g/min for 18 to 24 hours until 1 hour after completion of second angiography and PTCA. During study drug infusion, ischemia occurred in 9 c7E3 Fab and 16 placebo patients (P=.06). During hospital stay, 12 major events occurred in 7 placebo patients (23%), including 1 death, 4 infarcts, and 7 urgent interventions. In the T he term "unstable angina" encompasses a range of clinical situations related to sudden worsening of preexisting coronary disease.12 The underlying pathophysiological mechanism is a dynamic process, thought to begin with rupture of an atherosclerotic plaque and ulceration of the plaque surface, leading to platelet aggregation and nonocclusive or occlusive thrombosis. [3] [4] [5] In most patients, resolution of the thrombus and stabilization of the plaque will occur, and further ischemic symptoms can be prevented with bed rest and drugs that reduce myocardial oxygen consumption and prevent thrombosis.267 In a subgroup of patients, however, ischemic episodes continue despite intensive antianginal therapy, including nitrates, 13-blocking agents, heparin, and aspirin.2 Patients with such "refractory angina" are usually offered urgent percutaneous transluminal coronary angioplasty (PTCA) or coronary artery bypass graft surgery (CABG), even though these urgent procedures are associated with increased morbidity and P=.03). Angiography showed improved TIMI flow in 4 placebo and 6 c7E3 Fab patients and worsening of flow in 3 placebo patients but in none of the c7E3 Fab patients. Quantitative analysis showed significant improvement of the lesion in the patients treated with c7E3 Fab, which was not observed in the placebo group, although the difference between the two treatment groups was not significant. Measurement of platelet function and bleeding time demonstrated >90% blockade of GPIIb/IIIa receptors, >90% reduction of ex vivo platelet aggregation to ADP, and a significantly prolonged bleeding time during c7E3 Fab infusion, without excess bleeding.
Conclusions Combined therapy with c7E3 Fab, heparin, and aspirin appears safe. These pilot study results The chimeric 7E3 (c7E3) monoclonal antibody Fab fragment is a potent inhibitor of platelet aggregation. The antibody inhibits aggregation by blocking the glycoprotein (GP) 1Ib/IIIa receptor on the platelet surface, thereby blocking the final common pathway of platelet activation and aggregation. [17] [18] [19] In a double-blind randomized placebo-controlled pilot study, the safety and preliminary efficacy of c7E3 Fab treatment were studied in patients with refractory unstable angina who were undergoing PTCA. It was hypothesized that c7E3 Fab in combination with nitrates, heparin, and aspirin would facilitate stabilization of the culprit coronary lesion and thus reduce recurrent ischemia during the waiting period for PTCA and reduce the complication rate during and after the PTCA procedure. The effect of c7E3 Fab on the severity of the culprit coronary lesion was assessed by quantitative angiographic analysis. The difference between the incidence of multivessel disease between the two groups was statistically signfficant (P<.05).
sive and similar in both groups (Table 1) . During the study drug infusion, all patients received intravenous nitrates and heparin, and all but two (one in each group) received aspirin. The ECG changes during ischemia before enrollment were also similar.
Recurrent Ischemia
During infusion of the study drug, ischemia occurred in 9 patients treated with c7E3 Fab and in 16 placebo patients (P=.06), whereas 9 and 6 patients, respectively, developed ischemia after PTCA ( (Table 4 ). After treatment, the flow was improved in six patients in the c7E3 Fab group. In the placebo group, flow improved in four and worsened in three patients. Although slightly more thrombi were seen in the c7E3 Fab group at baseline, the number of thrombi was reduced by the same number in both groups.
Quantitative analysis of the ischemia-related segment did not reveal any changes during the study period in the placebo group (Table 4) . Conversely, between the first and second angiograms, an increase in minimal luminal diameter and significant reductions in the percent diameter stenosis, plaque area, and stenosis length were observed in the c7E3 Fab-treated patients. Nevertheless, direct comparison of the changes between the two treatment groups failed to reach statistical significance, which may be because of the sample size in this pilot study. Patients with events during study drug infusion including second angiography and PTCA (A) or after discontinuation of study drug until discharge (B).
One major event occurred in 1 c7E3 Fab patient 3 days after PTCA, whereas 12 events occurred in 7 placebo patients. In the placebo group, 3 patients had multiple events.
*A 61 -year-old man died after a complicated clinical course, including two urgent PTCA procedures because of severe recurrent ischemia and myocardial infarction. Heart failure and hypotension were treated with an intra-aortic balloon pump and mechanical ventilation. Severe bleeding occurred at puncture sites and gastric and pulmonary sites, for which a total of 17 (Figure) . Approximately 48 hours after the end of the infusion (t=72 hours), this number had returned to 61% of the baseline value. Platelet aggregation showed a similar inhibition of platelet function after c7E3 Fab infusion. Two hours after the start of the infusion, aggregation in response to 2, 5, and 20
gmol ADP was reduced to 0%, 0%, and 17% of the baseline value, respectively, and was returned to 61%, 66%, and 77% approximately 48 hours after the end of the infusion. In the subset of patients in whom these measurements were obtained, no relation was observed between the level of platelet inhibition and either recurrent ischemia or bleeding complications. One patient who was treated with c7E3 Fab did not show a significant inhibition of the platelet function (Figure) . Soon after the start of the study infusion, thrombocytosis was discovered in this patient, with platelet counts of 957 000/mm3. Bleeding times were measured by different methods (Ivy, Simplate, and Duke). Seven patients had a prolonged bleeding time at baseline, which could be explained by measurement after start of the infusion in two patients and concomitant aspirin use in the others. A prolongation of bleeding time exceeding twice the baseline value was observed in 18 of 23 patients during infusion with c7E3 Fab and in only 3 of 27 placebo patients (P<.001).
Complications
There were no bleeding events requiring surgical intervention. Five patients received blood transfusions, three in the c7E3 Fab group and two in the placebo group. According to the TIMI criteria, major bleeding occurred in one patient after treatment with c7E3 Fab and in three patients after placebo treatment. Minor bleeding was observed in one placebo patient but not in the c7E3 Fab patients. 25 and the severity of the culprit lesion was improved (Table 4) . The proportion of patients with major events, as specified in Table 3 , in the placebo group was 23%, which is comparable to the incidence of 36% in a previous study with similar design.12 Urgent PTCA in such patients has been associated with a 10% to 15% complication rate.1"12 A similarly high complication rate (30%) was observed in the present placebo group.
This study was randomized and conducted in a double-blind manner. Nevertheless, the results are not conclusive, because the number of patients in this pilot study is small and because an imbalance of baseline characteristics existed in favor of the c7E3 Fab-treated patients. In particular, the presence of multivessel disease was more frequent (P<.05), and more patients had previous angina (P=NS) in the placebo group. Furthermore, it cannot be excluded that the investigators became aware of the actual treatment in some patients because of prolonged bleeding times measured during c7E3 Fab therapy. However 
